+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Therapies - Global Strategic Business Report

  • PDF Icon

    Report

  • 915 Pages
  • March 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 834980

Economic Outlook

The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US$6 trillion economy by 2030, surpassing Japan and Germany.

The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.

Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Cancer Therapies Market to Reach $335.9 Billion by 2030

The global market for Cancer Therapies estimated at US$171.6 Billion in the year 2022, is projected to reach a revised size of US$335.9 Billion by 2030, growing at a CAGR of 8.8% over the analysis period 2022-2030. Chemotherapy, one of the segments analyzed in the report, is projected to record 8.1% CAGR and reach US$97 Billion by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $67.6 Billion, While China is Forecast to Grow at 10.3% CAGR

The Cancer Therapies market in the U.S. is estimated at US$67.6 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$27.9 Billion by the year 2030 trailing a CAGR of 10.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.4% and 9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.

Select Competitors (Total 80 Featured)

  • Bristol-Myers Squibb Company
  • Astellas Pharma, Inc.
  • Bayer AG
  • Bavarian Nordic A/S
  • Bayer Corporation
  • BioLineRx Ltd.
  • Antigen Express, Inc.
  • Aptose Biosciences, Inc.
  • Biodesix, Inc.
  • Adastra Labs Holdings Limited
  • Bayer AG, Pharmaceuticals
  • Anchiano Therapeutics, Inc.
  • Adastra Pharmaceuticals, Inc.
  • APT Asia Pacific
  • Celgene Corporation

What`s New?

  • Special discussions on the global economic climate and market sentiment
  • Coverage on global competitiveness and key competitor percentage market shares
  • Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and trademarked research platform
  • Complimentary updates for one year
  • Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes
Frequently Asked Questions about the Cancer Therapies Market

What is the estimated value of the Cancer Therapies Market?

The Cancer Therapies Market was estimated to be valued at $171.6 Billion in 2022.

What is the growth rate of the Cancer Therapies Market?

The growth rate of the Cancer Therapies Market is 8.8%, with an estimated value of $335.9 Billion by 2030.

What is the forecasted size of the Cancer Therapies Market?

The Cancer Therapies Market is estimated to be worth $335.9 Billion by 2030.

Who are the key companies in the Cancer Therapies Market?

Key companies in the Cancer Therapies Market include Bristol, Myers Squibb Company, Astellas Pharma, Inc., Bayer AG, Bavarian Nordic A/S, Bayer Corporation, BioLineRx Ltd., Antigen Express, Inc., Aptose Biosciences, Inc. and Biodesix, Inc..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Cancer Therapies: An Outlook
  • Chemotherapy & Targeted Therapy Lead the Global Cancer Therapies Market
  • By Cancer Type
  • USA Leads the Cancer Therapies Market
  • Biotherapies to Drive Growth
  • Rise in Cancer Incidence & Access to Modern Therapeutics Foster Growth
  • Total Number of New Cancer Cases by Type: 2018
  • Total Number of Cancer Deaths by Type: 2018
  • Cancer Incidence by Region: 2018
  • Cancer Mortality by Region: 2018
  • Age-Standardized Incidence and Mortality Rates of All Cancers (per 100000 Population) by Region: 2018
  • Cancer Research Spending Continues to Witness Growth
  • Number of FDA-Approved Cancer Drugs: 2010-2018
  • Select Cancer Drug Approvals in 2019
  • Select Cancer Drug Approvals in 2018
  • Cancer Drug Pipeline to Change the Pharma Landscape
  • Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019
  • Cancer Therapies - Global Key Competitors Percentage Market Share in 2023 (E)
  • Select Leading Cancer Drugs Worldwide by Sales: 2018
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
2. FOCUS ON SELECT PLAYERS
  • AbbVie, Inc. (USA)
  • Amgen, Inc. (USA)
  • Astellas Pharma, Inc. (Japan)
  • AstraZeneca Plc. (UK)
  • Bayer AG (Germany)
  • Bristol-Myers Squibb Company (USA)
  • Select Late Stage Compounds in Bristol-Myers Squibb Company’s Oncology Pipeline (As of 2019)
  • Celgene Corporation (USA)
  • Eli Lilly and Company (USA)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Glaxosmithkline Plc (UK)
  • Johnson & Johnson Services, Inc. (USA)
  • Merck KGaA (Germany)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (USA)
  • Takeda Pharmaceutical Company Limited (Japan)
3. MARKET TRENDS & DRIVERS
  • Industry Focuses on New Approaches to Treat Cancer
  • Recent Advancements in Cancer Drug Discovery
  • A New Immunotherapy Technique that Improves Efficacy and Safety of Cancer Treatment Developed by an Institute for Molecular Engineering Research Team
  • Lymphoma Therapy Developed by BeiGene Secures US FDA Approval
  • New Linker Technology for Enhancing Stability of ADCs
  • Personalized Medicine Gains Importance
  • Companion Diagnostics Accelerate Role of Personalized Medicine in Cancer Care
  • North American Companion Diagnostics Market (2019)
  • European Companion Diagnostics Market by Disease Area (2019)
  • Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation
  • Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Cancer Drugs
  • Combination Therapy: A Double Whammy Success
  • Patent Expiries of Branded Drugs to Trigger Generic Competition
  • Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe
  • Gene Therapy based Approaches Present Potential Weapon for Battle against Cancer
  • Development of Novel Drug Candidates and Potential Therapies
  • Non-Viral Gene Therapy to Expedite Cancer Research and Introduction of New Therapies
  • Rise in Patient Assistance Programs (PAPs)
  • Top Financial Concerns for Cancer Patients: Ranked In Order of Influence
  • Oral Oncolytic Abandonment Rate (in %) by Patient Out-of-Pocket Expenses
  • Growth Drivers and Restraints
  • Demographics & Lifestyles Raise the Risk of Cancer
  • Percentage Breakdown of New Cases for All Cancers by Gender (2019)
  • Percentage Breakdown of New Cases for Colon and Rectum Cancers by Gender (2019)
  • Percentage Breakdown of New Cases for Lung & Bronchus Cancers by Gender (2019)
  • Unmet Needs Leave Scope for Further Research and Development
  • Low Entry Barriers in Cancer Research Encourages Breakthrough Developments
  • Increasing Investments by National Health Authorities
  • NCI Funding for Cancer Research (2002, 2008, 2014 and 2020)
  • Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth
  • Molecular Imaging of Cancer: Critical in Improving Patient Outcomes
  • Innovations, Improvements, and Approvals Propel Growth
  • Select Cancer Drug Approvals (2018 & 2019)
  • Emerging Challenges in Cancer Drug Development
  • Drug Failures Deter Prospects of New Therapies
  • High Prices of Targeted Therapies Act as a Speed Breaker
  • Estimated Average Monthly Cost of Select Leading Cancer Drugs in the US as of 2016
  • Cancer Drug Approval Processes Need to Become More Flexible for Encouraging Innovation
  • Limited Tumor Specificity and Toxicity
  • Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance
  • Reduced Smoking
  • Global Cigarette Consumption Per Capita by Select Countries for 1970 and 2018
  • Reimbursement Coverage Remains a Major Challenge
  • Increase in Multidrug Resistance
  • Stringent Regulations Delay Market Approval
  • Challenges Encountered in Clinical Trials
  • Overview of Cancer Therapy Segments
  • Immunotherapy: A Promising Segment
  • Global Cancer Immunotherapy Market by Therapy Type (in %) for 2019
  • Monoclonal Antibodies for Cancer Treatment
  • Monoclonal Antibodies in Late-Stage Clinical Trials for Cancer Treatment
  • Vaccines: A Promising Future Area of Cancer Therapeutics
  • Approved Therapeutic Cancer Vaccines Worldwide
  • CAR-T Therapy: An Innovative Therapy Focused on Engineering of Patients’ Immune Cells for Cancer Treatment
  • UK Researchers New Approach Holds Potential to Boost Immunotherapies
  • Targeted Therapy: An Overview
  • Types of Targeted Therapy
  • Chemotherapy: An Overview
  • Types of Chemotherapy
  • Risks Associated with Chemotherapy
  • Hormone Therapy
  • Drug Classes in Hormone Therapy
  • CANCER TYPES, APPROVED AND PIPELINE DRUGS
  • Prostate Cancer
  • Global Sales of Leading Prostate Cancer Drugs in US$ Million: 2018
  • Select General Risk Factors and their Relative Risk Rate in Prostate Cancer
  • Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer
  • Select Drugs that Received Approval for Castration-Resistant Prostate Cancer (CRPC)
  • Prostate Cancer Phase IV Completed Clinical Trials with Results
  • Lung Cancer
  • Age-Standardized Lung Cancer Rates for Select Countries
  • Age-Standardized Lung Cancer Rates in Men for Select Countries
  • Age-Standardized Lung Cancer Rates in Women for Select Countries
  • Select FDA-Approved Non-Small Cell Lung Cancer Drugs
  • Select Phase IV Completed Clinical Trials with Results: As of Dec, 2019
  • Select Phase III Completed Clinical Trials with Results: As of December 30, 2019
  • Breast Cancer
  • Select FDA Approved Breast Cancer Drugs
  • Breast Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019
  • Breast Cancer Select Phase III Completed Clinical Trials with Results: As of Dec 30, 2019
  • Renal Cancer
  • Select FDA-Approved Renal Cell Carcinoma Drugs
  • Cervical Cancer
  • Colorectal Cancer
  • Select FDA-Approved Colorectal Cancer Drugs
  • Skin Cancer
  • Pancreatic Cancer
  • Non-Hodgkin’s Lymphoma
  • Leukemia
  • Standard Approved Mode of Therapy for AML by Age Group
  • Blood Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019
  • Blood Cancer Phase III Completed Clinical Trials with Results: As of Dec 30, 2019
  • Bladder Cancer
  • Endometrial Cancer
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Cancer Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 3: World 16-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 6: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 9: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 12: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 15: World 16-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 18: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 21: World 16-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 24: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 25: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 26: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 27: World 16-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Gastrointestinal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 29: World Historic Review for Gastrointestinal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 30: World 16-Year Perspective for Gastrointestinal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 31: World Recent Past, Current & Future Analysis for Gynecologic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 32: World Historic Review for Gynecologic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 33: World 16-Year Perspective for Gynecologic Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 34: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 35: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 36: World 16-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 37: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 38: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 39: World 16-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 40: World Cancer Therapies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Market Overview
  • Rising Cancer Cases Spur Growth in Cancer Therapies Market
  • Estimated Number of New Cancer Cases and Deaths in the US (2019)
  • Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018
  • Number of FDA-Approved Oncology Drugs in the US (2010-2018)
  • Cancer Drugs as % of Drug Pipeline in the US for the Period 2010-2019
  • Patient Assistance Programs Alleviate Cost Burden of Patients to Some Extent
  • Personalized Medicine Gathers Momentum for Cancer Treatment in the US
  • A Surging US Prostate Cancer Therapeutics Market
  • Medicaid Reimbursement Rates for Cancer Treatment with Radiation Indicate Notable Disparity among States
  • Oncology Care Model to Improve Quality and Reduce Financial Toxicity of Cancer Care
  • CMS Hikes Reimbursement Rate for CAR-T Therapy
  • Market Analytics
  • CANADA
  • Number of New Cancer Cases in Canada: 2019
  • JAPAN
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • CHINA
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Cancer Therapies Market: Overview
  • Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018
  • Chinese Drug Makers Look to Strengthen Domestic Presence with Low-cost Products
  • EUROPE
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market
  • Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
  • Number of New Cancer Cases Diagnosed (in Thousands) in the UK: 2018
  • FRANCE
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • GERMANY
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • ITALY
  • UNITED KINGDOM
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • SPAIN
  • RUSSIA
  • REST OF EUROPE
  • ASIA-PACIFIC
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • An Insight into Asia-Pacific Market for Cancer Therapies
  • Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019
  • AUSTRALIA
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
  • INDIA
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
  • SOUTH KOREA
  • REST OF ASIA-PACIFIC
  • LATIN AMERICA
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
  • ARGENTINA
  • BRAZIL
  • MEXICO
  • REST OF LATIN AMERICA
  • MIDDLE EAST
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
  • IRAN
  • ISRAEL
  • SAUDI ARABIA
  • UNITED ARAB EMIRATES
  • REST OF MIDDLE EAST
  • AFRICA
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Bristol-Myers Squibb Company
  • Astellas Pharma, Inc.
  • Bayer AG
  • Bavarian Nordic A/S
  • Bayer Corporation
  • BioLineRx Ltd.
  • Antigen Express, Inc.
  • Aptose Biosciences, Inc.
  • Biodesix, Inc.
  • Adastra Labs Holdings Limited
  • Bayer AG, Pharmaceuticals
  • Anchiano Therapeutics, Inc.
  • Adastra Pharmaceuticals, Inc.
  • APT Asia Pacific
  • Celgene Corporation